Markets:

Overview

News

Currencies

International

Treasuries

Ionis Pharmaceuticals, Inc. - Common Stock (NQ:IONS)

78.66 +1.13 (+1.46%)

Streaming Delayed Price Updated: 11:02 AM EST, Jan 21, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Ionis Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

The RNAi Powerhouse: A Deep Dive into Alnylam Pharmaceuticals’ Path to the S&P 500

January 02, 2026

As the calendar turns to 2026, Alnylam Pharmaceuticals (Nasdaq: ALNY) stands at the threshold of a new era. Once a speculative pioneer in the arcane world of RNA interference (RNAi), the...

Via PredictStreet

Metagenomi Prioritizes Hemophilia A Program, Lays Off 25% Workforce ↗

November 12, 2025

Metagenomi reports curative-level FVIII activity for MGX-001 in primates and plans IND filing in 2026, extending cash runway into late 2027.

Via Benzinga

Ionis Reports Substantial Drop In Acute Pancreatitis Events With Cholesterol Lowering Drug ↗

November 10, 2025

Ionis' olezarsen cut triglycerides by up to 72% and reduced acute pancreatitis events by 85% in Phase 3 studies of severe hypertriglyceridemia.

Via Benzinga

Earnings Scheduled For October 29, 2025 ↗

October 29, 2025

Via Benzinga

Ionis Pharmaceuticals Earnings Preview ↗

October 28, 2025

Via Benzinga

Ionis Pharma Stock Rises After Multiple Price Target Hikes On Heels Of Positive Study Results In Alexander Disease ↗

September 23, 2025

Via Stocktwits

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

November 10, 2025

Via Benzinga

Monday.Com, Metsera, Profrac Holding And Other Big Stocks Moving Lower In Monday's Pre-Market Session ↗

November 10, 2025

Via Benzinga

Why Viasat Shares Are Trading Higher By Around 13%; Here Are 20 Stocks Moving Premarket ↗

November 10, 2025

Via Benzinga

Intellia Therapeutics Crashes After A Patient In Its Pivotal Study Dies ↗

November 07, 2025

The company remains confident in its other gene-editing product, which would treat a swelling disorder.

Via Investor's Business Daily

Topics Death

Cathie Wood Goes All-In On Peter Thiel's Crypto Play Bullish With Back-To-Back Million-Dollar Buys ↗

November 04, 2025

Cathie Wood-led Ark Invest purchased shares in Bullish, a crypto exchange backed by Peter Thiel, through three of its funds. Other key trades were also made, including buying shares in CRISPR and Beam...

Via Benzinga

Ionis (IONS) Q3 2025 Earnings Call Transcript ↗

October 30, 2025

Ionis (IONS) Q3 2025 Earnings Call Transcript

Via The Motley Fool

Topics Earnings

Alnylam Stock Has Already Doubled In 2025. Why It Could Rocket Again On Earnings. ↗

October 30, 2025

The company easily beat third-quarter expectations and issued guidance that widely topped forecasts.

Via Investor's Business Daily

Alphabet To Rally Around 22%? Here Are 10 Top Analyst Forecasts For Thursday ↗

October 30, 2025

Via Benzinga

Capricorn Buys New Stake in Ionis Pharmaceuticals (IONS) With 163,000 Shares ↗

October 20, 2025

Via The Motley Fool

31 Analysts Assess Ionis Pharmaceuticals: What You Need To Know ↗

October 16, 2025

Via Benzinga

IONIS PHARMACEUTICALS INC (NASDAQ:IONS) Shows Strong Growth Momentum and Technical Strength ↗

October 15, 2025

IONIS Pharmaceuticals stock shows strong technical and fundamental momentum, meeting strict trend-following criteria with surging earnings and revenue growth.

Via Chartmill

Ionis Pharmaceuticals (NASDAQ:IONS) Ascends to Six-Year High, Fueled by Breakthrough Pipeline and Robust Sales Outlook

October 08, 2025

Carlsbad, CA – October 8, 2025 – Ionis Pharmaceuticals (NASDAQ:IONS) is currently witnessing a remarkable surge in its stock value, nearing a six-year high. This impressive ascent is largely driven by...

Via MarketMinute

Why Ionis Stock, Approaching A Six-Year High, Just Snagged A Price-Target Hike ↗

October 08, 2025

The company is working toward a potential $5 billion sales peak for its partnered and unpartnered programs.

Via Investor's Business Daily

This Penumbra Analyst Turns Bullish; Here Are Top 4 Upgrades For Wednesday ↗

October 08, 2025

Via Benzinga

What Analysts Are Saying About Ionis Pharmaceuticals Stock ↗

September 23, 2025

Via Benzinga

Ionis Pharmaceuticals Reveals 'Unprecedented Results' From Rare Neurological Disease Trial ↗

September 22, 2025

Ionis reports positive pivotal study results for zilganersen in Alexander disease, showing gait speed benefits and strong safety data.

Via Benzinga

Ionis Pharmaceuticals To Expedite Development Of Rare Neurological Disease Candidate With FDA Breakthrough Status ↗

September 09, 2025

FDA designates Ionis Breakthrough Therapy for Angelman syndrome after Phase 1/2 results showed functional improvements.

Via Benzinga

Here are the top movers in Tuesday's session. ↗

September 02, 2025

Here are the top movers in Tuesday's session, showcasing the stocks with significant price changes.

Via Chartmill

IONS Stock Soars 34% To Hit February 2021 Highs After Medicine Shows Positive Effect On Elevated Triglyceride Levels In Late-Stage Studies ↗

September 02, 2025

In two studies, Ionis’ Olezarsen demonstrated a highly statistically significant placebo-adjusted mean reduction in fasting triglycerides of up to 72% at six months.

Via Stocktwits

12 Health Care Stocks Moving In Tuesday's Intraday Session ↗

September 02, 2025

Via Benzinga

Air Lease, Ionis Pharmaceuticals, Arrowhead Pharmaceuticals And Other Big Stocks Moving Higher On Tuesday ↗

September 02, 2025

Via Benzinga

Ionis Pharma's Investigational Drug Shows Promise For Triglyceride And Pancreatitis Reduction ↗

September 02, 2025

Ionis posted positive Phase 3 results for olezarsen in severe hypertriglyceridemia, showing 72% triglyceride reduction and 85% fewer pancreatitis events.

Via Benzinga

There are notable gap-ups and gap-downs in today's session. ↗

September 02, 2025

The session on Tuesday is off to an intriguing start with several stocks showing significant price gaps. Let's examine the gap up and gap down stocks in today's session.

Via Chartmill

Ionis Pharma Hits The 'Bull Case,' 'Blue Sky' In Lowering Triglycerides. Shares Launch. ↗

September 02, 2025

Ionis Pharmaceuticals scored the "bull case" Tuesday after its experimental treatment for high triglycerides beat the placebo.

Via Investor's Business Daily

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.